A total of 43 innovative new medicines are anticipated to be approved or listed in Japan this year, according to a survey by Jiho. At the center of attention are some highly innovative, but probably ultra-expensive, gene therapies, as well…
HOME > ORGANIZATION
ORGANIZATION
- Generic Market Share Increases Marginally to 23.3% in FY2011: JGA
June 18, 2012
- Drugs Developed in Response to Gov’t Request Should Be Exempted from Downward Foreign Average Price Adjustment: FPMAJ
June 13, 2012
- 48 Products Subjected to Market Expansion Re-Pricing in FY2012: FPMAJ Survey
June 13, 2012
- Products Re-Priced Due to Market Expansion Should Be Eligible for New Drug Premium to Promote Innovation: FPMAJ
June 12, 2012
- FPMAJ’s Subcommittee Calls for Discussion on Need for “Ad Hoc Price Reduction” for Long-Listed Drugs
June 12, 2012
- FPMAJ’s NHI Drug Price Study Committee to Set Up Task Forces for Long-Listed Products, Cost Effectiveness
June 11, 2012
- Chairman Kamoya of FPMAJ’s Committee on NHI Drug Pricing Expresses Concern Over Long-Listed Drugs
June 11, 2012
- JAPMS to Establish Working Group on Improvement of Drug Distribution
June 6, 2012
- JMA Board Members Caution Against Rush to Introduce Cost-Effective Assessment: Dr Suzuki
June 5, 2012
- MREAC to Release Passing Scores for MR Exam Starting This Year
June 4, 2012
- JMA Requests FPMAJ, JPMA to Set Up Nursery Care Facilities for Lectures
June 4, 2012
- Head of Wholesale Industry FTC Calls for Compliance with Competition Code as Violation Cases Increase to Five
May 29, 2012
- Capital Investment Needed for Bar Code Labeling Estimated at About 700 Million Yen Per Drug Maker: JPWA, JPMA Survey
May 28, 2012
- Three Head Office-Level Violations of Fair Competition Code in FY2011: Drug Marketing Industry’s FTC
May 23, 2012
- Greater Centralization, Clarity Needed in Formulating Medical Innovation Policy: Dr Teshirogi of JPMA
May 21, 2012
- Pharma Industry FTC Implements New GL on Restriction of Business Entertaining Rules, Without Acceptance of CAA
May 21, 2012
- JPMA Approves MTPC’s Re-Enrollment 16 Months after Quitting
May 18, 2012
- “Cost-Effective Assessment Inhibits Innovation”: FPMAJ Chairman Naito
May 18, 2012
- Interview with Alfonso G. Zulueta of PhRMA
May 14, 2012
- Greater Concern than Hope about HTA: Mr Zulueta of PhRMA
May 14, 2012
ページ
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…